77876 Federal Register / Vol. 89, No. 185 / Tuesday, September 24, 2024 / Notices 

Publications: Protective human 

monoclonal antibodies target conserved 

sites of vulnerability on the underside of 

influenza virus neuraminidase. 

Lederhofer, Julia et al. Immunity, 

Volume 57, Issue 3, 574–586.e7. 

Intellectual Property: PCT/US2023/ 

071194 filed 28 July 2023 (NIH Ref. No. 

E–177–2022). 

Licensing Contact: To license this 

technology, please contact Haiqing Li at 

240–627–3708, or lihai@mail.nih.gov, 

and reference E–177–2022. 

Dated: September 18, 2024. 

Christopher M. Kornak, 

Acting Deputy Director, Technology Transfer 

and Intellectual Property Office, National 

Institute of Allergy and Infectious Diseases. 

[FR Doc. 2024–21742 Filed 9–23–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Time-Sensitive 

Obesity review. 

Date: October 29, 2024. 

Time: 2:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, NIDDK 

Democracy II, Suite 7000A, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Michele L. Barnard, Ph.D., 

Scientific Review Officer, National Institute 

of Diabetes and Digestive and Kidney, 

National Institute of Health, 6707 Democracy 

Boulevard, Rm. 7353, Bethesda, MD 20892– 

2542, (301) 594–8898, barnardm@

extra.niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: September 18, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–21737 Filed 9–23–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer on (240) 276–0361. 

Proposed Project: New: The Center for 

Substance Abuse Prevention Online 

Reporting Tool and Grant Programmatic 

Progress Report to replace Division of 

State Programs—Management Reporting 

Tool (DSP–MRT) (OMB No. 0930–0354). 

The Substance Abuse and Mental 

Health Services Administration’s 

(SAMHSA), Center for Substance Abuse 

Prevention (CSAP) is requesting 

approval from the Office of Management 

and Budget (OMB) to monitor CSAP 

discretionary grant programs through 

administration of a suite of data 

collection instruments for grant 

compliance and programmatic 

performance monitoring. 

This package describes the data 

collection activities and proposed 

instruments. Grant compliance 

monitoring will be conducted via a 

single data collection instrument to be 

completed by all CSAP discretionary 

grant recipients. Programmatic 

performance monitoring will be 

conducted via a suite of data collection 

instruments with each instrument 

tailored to a specific CSAP discretionary 

program. This request for data collection 

will replace OMB No. 0930–0354: 

Division of State Programs— 

Management Reporting Tool. 

CSAP intends to monitor six grant 

programs through this data collection 

effort: 

• Strategic Prevention Framework— 

Partnerships for Success (SPF–PFS): The 

purpose of the SPF–PFS program is to 

help reduce the onset and progression of 

substance misuse and its related 

problems by supporting the 

development and delivery of state and 

community substance misuse 

prevention and mental health 

promotion services. This program is 

intended to promote substance use 

prevention throughout a state 

jurisdiction for individuals and families 

by building and expanding the capacity 

of local community prevention 

providers to implement evidence-based 

programs. In addition, the program is 

intended to expand and strengthen the 

capacity of local community prevention 

providers to implement evidence-based 

prevention programs. With this 

program, SAMHSA aims to strengthen 

state and community level prevention 

capacity to identify and address local 

substance use prevention concerns, 

such as underage drinking, marijuana, 

tobacco, electronic cigarettes, opioids, 

methamphetamine, and heroin. 

• Sober Truth on Preventing 

Underage Drinking (STOP Act): The 

purpose of this program is to prevent 

and reduce alcohol use among youth 

and young adults ages 12–20 in 

communities throughout the United 

States through evidence-based 

screening, programs and curricula, brief 

intervention strategies, consistent policy 

enforcement, and environmental 

changes that limit underage access to 

alcohol as authorized by 42 U.S.C. 

290bb–25b. The program aims to: (1) 

address norms regarding alcohol use by 

youth, (2) reduce opportunities for 

underage drinking, (3) create changes in 

underage drinking enforcement efforts, 

(4) address penalties for underage use, 

and/or (5) reduce negative consequences 

associated with underage drinking. 

• Strategic Prevention Framework for 

Prescription Drugs (SPF Rx): The 

purpose of the SPF Rx grant program is 

to provide resources to help prevent and 

address prescription drug misuse within 

a State or locality. The program is 

designed to raise awareness about the 

dangers of sharing medications as well 

as the risks of fake or counterfeit pills 

purchased over social media or other 

unknown sources, and work with 

pharmaceutical and medical 

communities on the risks of 

overprescribing. Whether addressed at 

the state level or by an informed 

community-based organization, the SPF 

Rx program will raise community 

awareness and bring prescription 

substance misuse prevention activities 

and education to schools, communities, 

parents, prescribers, and their patients. 

In addition, grant recipients will be 

required to track reductions in opioid 

related overdoses and incorporate 

relevant prescription and overdose data 


lotter on DSK11XQN23PROD with NOTICES1